In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits ...

Lilly is still worth over $500 billion, but its market capitalisation has shed almost a third in the past year. With ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

Pharmaceutical giant Eli Lilly said last week that it will raise the U.K. list price of its weight-loss treatment Mounjaro by ...

Eli Lilly, the maker of the popular injectable Mounjaro, has just released the surprising phase 3 trial results for its new ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

The experimental obesity medicine is one of two that could offer alternatives to weight-loss injections within the next year ...

Then, last year, observers were astonished when Lilly’s tirzepatide elicited nearly 20% weight loss in a Phase 3 study. Now, Lilly’s latest drug has set the bar for weight loss even higher.